ENZON INC
8-K, 2000-03-21
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Previous: GLOBAL CASINOS INC, 10QSB/A, 2000-03-21
Next: ENZON INC, 424B4, 2000-03-21






                                  UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549


                                    FORM 8-K
                                 CURRENT REPORT

                       Pursuant to Section 13 or 15(d) of
                       the Securities Exchange Act of 1934

        Date of Report (Date of earliest event reported): March 21, 2000

                                   ENZON, INC.
             (Exact name of registrant as specified in its charter)


Delaware                                0-12957            22-2372868
(State or other jurisdiction        (Commission File      (IRS Employer
of incorporation)                       Number)         Identification No.)



20 Kingsbridge Road            Piscataway, New Jersey                      08854
(Address of principal executive offices)                              (Zip Code)



Registrant's telephone number, including area code (732) 980-4500


<PAGE>


Item 5.  Other Events.

     Enzon, Inc.,  announced that it has priced its public offering of 2 million
newly issued  shares of common stock at $44.50 per share.  Enzon has granted the
underwriters an option to purchase an additional  300,000 shares of common stock
to cover  over-allotments,  if any. The net proceeds to Enzon are expected to be
approximately  $83.1  million,  after  deducting   underwriters'  discounts  and
commissions and offering  expenses ($95.7 million if the  underwriters  exercise
their over-allotment option in full). The managing underwriters for the offering
are Morgan  Stanley  Dean  Witter,  CIBC World  Markets and SG Cowen  Securities
Corporation.

     A registration  statement  relating to these  securities was filed with and
declared effective by the Securities and Exchange Commission. This press release
shall not constitute an offer to sell or a  solicitation  of an offer to buy nor
shall  there be any sale of these  securities  in any state in which such offer,
solicitation or sale would be unlawful prior to  registration  or  qualification
under the securities laws of such state.

     A copy of the  Prospectus  relating to the  offering  may be obtained  from
Morgan Stanley Dean Witter,  Attn:  Prospectus  Department,  1585 Broadway,  New
York, New York, 10036-8293,  when available. The registration statement can also
be viewed on the Internet at http://www.sec.gov.


                                       2

<PAGE>


SIGNATURE

     Pursuant to the  requirements  of the Securities  Exchange Act of 1934, the
Registrant  has duly  caused  this  Report  to be  signed  on its  behalf by the
undersigned hereunto duly authorized.

Dated:   March 21, 2000

                                                 ENZON, INC.
                                                 -----------
                                                 (Registrant)


                                             By:  /s/ Kenneth J. Zuerblis
                                                  -----------------------
                                             Kenneth J. Zuerblis
                                             Vice President, Finance
                                             and Chief Financial Officer




                                       3



© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission